3-deoxyglucosone has been researched along with Diabetic Neuropathies in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alouffi, S; Khan, MWA | 1 |
| Hamada, Y; Horiuchi, S; Hotta, N; Kasuya, Y; Kato, K; Komori, T; Nagai, R; Nakamura, J; Naruse, K | 1 |
1 review(s) available for 3-deoxyglucosone and Diabetic Neuropathies
| Article | Year |
|---|---|
Dicarbonyls Generation, Toxicities, Detoxifications and Potential Roles in Diabetes Complications.
Topics: Deoxyglucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Neuropathies; Diabetic Retinopathy; Gene Expression Regulation; Glycation End Products, Advanced; Glyoxal; Humans; Insulin; Insulin Resistance; Isoenzymes; Lactoylglutathione Lyase; Oxidative Stress; Protein Carbonylation; Pyruvaldehyde; Signal Transduction | 2020 |
1 other study(ies) available for 3-deoxyglucosone and Diabetic Neuropathies
| Article | Year |
|---|---|
Epalrestat, an aldose reductase ihibitor, reduces the levels of Nepsilon-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients.
Topics: Aldehyde Reductase; Blood Glucose; Blood Proteins; Deoxyglucose; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Diabetic Retinopathy; Enzyme Inhibitors; Erythrocytes; Female; Glycated Hemoglobin; Glycation End Products, Advanced; Humans; Lysine; Male; Middle Aged; Reference Values; Rhodanine; Thiazolidines | 2000 |